

OMTO, Volume 14

Supplemental Information

**The Novel Oncolytic Compound LTX-401
Induces Antitumor Immune Responses
in Experimental Hepatocellular Carcinoma**

Brynjar Mauseth, Ketil André Camilio, Jihua Shi, Clara Louise Hammarström, Øystein Rekdal, Baldur Sveinbjörnsson, and Pål-Dag Line

Supplemental information




Figure S1. Cytotoxic activity of LTX-401 compared to doxorubicin and gemcitabine. JM1 cells were treated with the $2 \times IC_{50}$ value for LTX-401, doxorubicin and gemcitabine for designated time points (4, 24 and 48 hours) and assessed for viability using the MTT assay. Data represent the mean \pm SD of three independent experiments with triplicates for each.